Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.
CRTAC1 is a promising biomarker of osteoarthritis
CRTAC1 in plasma is a specific biomarker of osteoarthritis, a measure of OA risk, and a predictor of progression to joint replacements. The lack of a biomarker of osteoarthritis (OA) has hindered the development of effective therapies for this common disease.
First report from the world’s most ambitious sequencing project
Scientists at deCODE genetics a subsidiary of Amgen, together with collaborators from Denmark report on the whole genome sequences of 150 thousand participants in the UK biobank in a paper published in the journal Nature today.
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.